Daniel Benjamin Jr., MD, PhD, MPH



email this

Professor of Pediatrics
Faculty Associate Director, Duke Clinical Research Institute
Department / Division:
Pediatrics / Pediatrics-Infectious Diseases
Box 17969
Durham, NC 27715
Appointment Telephone:
Office Telephone:
  • MD, University of Virginia School of Medicine, 1995
  • MPH, University of North Carolina, 2001
  • PhD, Epidemiology, University of North Carolina–Chapel Hill, 2003
  • Pediatrics, University of Virginia Medical Center, 1998
  • Infectious Disease, Duke University Medical Center, 2001
Clinical Interests:
Infections in neonates and bone-marrow transplant patients, meningitis, use of diagnostic tests
Research Interests:

Dr. Danny Benjamin is the Principal Investigator and Chair of the National Institute of Child Health and Human Development’s Pediatric Trials Network. The Network is responsible for designing and leading clinical trials of off-patent medicines in children of all ages across all therapeutic areas. The team has established, or is actively studying, the correct dosing and safety of more than 50 of the most commonly used medicines in children. Each of these trials is conducted under an investigational new drug (IND) application with guidance from the Food and Drug Administration for labeling.

Signature programs of the Network include clinical trials in premature, term infants and most recently, obese children. Over the past 10 years, Dr. Benjamin’s group has enrolled more premature infants, at more sites, in more clinical trials of off-patent anti-infectives under an IND than all other academic medical centers, pharmaceutical companies, and government agencies in the world, combined.

Dr. Benjamin is recognized by the National Institutes of Health as a premiere mentor and educator. His research program serves as a platform to train students and early career investigators. Dr. Benjamin’s group has a clinical research summer program for high school and college students targeting under-represented minority students, and he is the primary mentor for medical students, residents, subspecialty fellows (including two T32 programs sponsored by NIH for which he is PI), and multiple junior faculty.

Dr. Benjamin has published over 250 works with up to 7000 citations. 

Representative Publications:
  • Cohen-Wolkowiez, M; Benjamin, DK; Piper, L; Cheifetz, IM; Moran, C; Liu, P; Aram, J; Kashuba, AD; Capparelli, E; Walsh, TJ; Hope, WW; Smith, PB. Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. Clinical Pharmacology & Therapeutics (Nature). 2011;89:702-707.  Abstract
  • Greenberg, RG; Benjamin, DK; Cohen-Wolkowiez, M; Clark, RH; Cotten, CM; Laughon, M; Smith, PB. Repeat lumbar punctures in infants with meningitis in the neonatal intensive care unit. Journal of Perinatology. 2011;31:425-429.  Abstract
  • Jean-Baptiste, N; Benjamin, DK; Cohen-Wolkowiez, M; Fowler, VG; Laughon, M; Clark, RH; Smith, PB. Coagulase-negative staphylococcal infections in the neonatal intensive care unit. Infection Control and Hospital Epidemiology. 2011;32:679-686.  Abstract
  • Piper, L; Smith, PB; Hornik, CP; Cheifetz, IM; Barrett, JS; Moorthy, G; Hope, WW; Wade, KC; Cohen-Wolkowiez, M; Benjamin, DK. Fluconazole loading dose pharmacokinetics and safety in infants. Pediatric Infectious Disease Journal. 2011;30:375-378.  Abstract
  • Smith, PB; Cohen-Wolkowiez, M; Castro, LM; Poindexter, B; Bidegain, M; Weitkamp, JH; Schelonka, RL; Ward, RM; Wade, K; Valencia, G; Burchfield, D; Arrieta, A; Bhatt-Mehta, V; Walsh, M; Kantak, A; Rasmussen, M; Sullivan, JE; Finer, N; Brozanski, BS; Sanchez, P; van den Anker, J; Blumer, J; Kearns, GL; Capparelli, EV; Anand, R; Benjamin, DK; Meropenem Study Team. Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections. Pediatric Infectious Disease Journal. 2011;30:844-849.  Abstract
  • Yanni, SB; Smith, PB; Benjamin, DK; Augustijns, PF; Thakker, DR; Annaert, PP. Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding. Biopharmaceutics and Drug Disposition. 2011;32:222-232.  Abstract
  • Benjamin, DK; Smith, PB; Arrieta, A; Castro, L; Sánchez, PJ; Kaufman, D; Arnold, LJ; Kovanda, LL; Sawamoto, T; Buell, DN; Hope, WW; Walsh, TJ. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clinical Pharmacology & Therapeutics (Nature). 2010;87:93-99.  Abstract
  • Benjamin, DK; Stoll, BJ; Gantz, MG; Walsh, MC; Sánchez, PJ; Das, A; Shankaran, S; Higgins, RD; Auten, KJ; Miller, NA; Walsh, TJ; Laptook, AR; Carlo, WA; Kennedy, KA; Finer, NN; Duara, S; Schibler, K; Chapman, RL; Van Meurs, KP; Frantz, ID; Phelps, DL; Poindexter, BB; Bell, EF; O'Shea, TM; Watterberg, KL; Goldberg, RN; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics. 2010;126:e865-e873.  Abstract
  • Greenberg, RG; Moran, C; Ulshen, M; Smith, PB; Benjamin, DK; Cohen-Wolkowiez, M. Outcomes of catheter-associated infections in pediatric patients with short bowel syndrome. Journal of Pediatric Gastroenterology and Nutrition. 2010;50:460-462.  Abstract
  • Hope, WW; Smith, PB; Arrieta, A; Buell, DN; Roy, M; Kaibara, A; Walsh, TJ; Cohen-Wolkowiez, M; Benjamin, DK. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrobial agents and chemotherapy. 2010;54:2633-2637.  Abstract
  • Cotten, CM; Taylor, S; Stoll, B; Goldberg, RN; Hansen, NI; Sánchez, PJ; Ambalavanan, N; Benjamin, DK; NICHD Neonatal Research Network. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics. 2009;123:58-66.  Abstract
  • Pappas, PG; Kauffman, CA; Andes, D; Benjamin, DK; Calandra, TF; Edwards, JE; Filler, SG; Fisher, JF; Kullberg, BJ; Ostrosky-Zeichner, L; Reboli, AC; Rex, JH; Walsh, TJ; Sobel, JD; Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2009;48:503-535.  Abstract
  • Smith, PB; Walsh, TJ; Hope, W; Arrieta, A; Takada, A; Kovanda, LL; Kearns, GL; Kaufman, D; Sawamoto, T; Buell, DN; Benjamin, DK. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatric Infectious Disease Journal. 2009;28:412-415.  Abstract
  • Wade, KC; Benjamin, DK; Kaufman, DA; Ward, RM; Smith, PB; Jayaraman, B; Adamson, PC; Gastonguay, MR; Barrett, JS. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatric Infectious Disease Journal. 2009;28:717-723.  Abstract
  • Benjamin, DK; Smith, PB; Jadhav, P; Gobburu, JV; Murphy, MD; Hasselblad, V; Baker-Smith, C; Califf, RM; Li, JS. Pediatric antihypertensive trial failures: analysis of end points and dose range. Hypertension. 2008;51:834-840.  Abstract
  • Greenberg, RG; Smith, PB; Cotten, CM; Moody, MA; Clark, RH; Benjamin, DK. Traumatic lumbar punctures in neonates: test performance of the cerebrospinal fluid white blood cell count. Pediatric Infectious Disease Journal. 2008;27:1047-1051.  Abstract
  • Hope, WW; Mickiene, D; Petraitis, V; Petraitiene, R; Kelaher, AM; Hughes, JE; Cotton, MP; Bacher, J; Keirns, JJ; Buell, D; Heresi, G; Benjamin, DK; Groll, AH; Drusano, GL; Walsh, TJ. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. Journal of Infectious Diseases. 2008;197:163-171.  Abstract
  • Smith, PB; Li, JS; Murphy, MD; Califf, RM; Benjamin, DK. Safety of placebo controls in pediatric hypertension trials. Hypertension. 2008;51:829-833.  Abstract
  • Wade, KC; Wu, D; Kaufman, DA; Ward, RM; Benjamin, DK; Sullivan, JE; Ramey, N; Jayaraman, B; Hoppu, K; Adamson, PC; Gastonguay, MR; Barrett, JS; National Institute of Child Health and Development Pediatric Pharmacology Research Unit Network. Population pharmacokinetics of fluconazole in young infants. Antimicrobial agents and chemotherapy. 2008;52:4043-4049.  Abstract
  • Cohen-Wolkowiez, M; Benjamin, DK; Fowler, VG; Wade, KC; Alexander, BD; Worley, G; Goldstein, RF; Smith, PB. Mortality and neurodevelopmental outcome after Staphylococcus aureus bacteremia in infants. Pediatric Infectious Disease Journal. 2007;26:1159-1161.  Abstract
  • Cohen-Wolkowiez, M; Smith, PB; Mangum, B; Steinbach, WJ; Alexander, BD; Cotten, CM; Clark, RH; Walsh, TJ; Benjamin, DK. Neonatal Candida meningitis: significance of cerebrospinal fluid parameters and blood cultures. Journal of Perinatology. 2007;27:97-100.  Abstract
  • Lenfestey, RW; Smith, PB; Moody, MA; Clark, RH; Cotten, CM; Seed, PC; Benjamin, DK. Predictive value of cerebrospinal fluid parameters in neonates with intraventricular drainage devices. Journal of neurosurgery. 2007;107:209-212.  Abstract
  • Li, JS; Eisenstein, EL; Grabowski, HG; Reid, ED; Mangum, B; Schulman, KA; Goldsmith, JV; Murphy, MD; Califf, RM; Benjamin, DK. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA : the journal of the American Medical Association. 2007;297:480-488.  Abstract
  • Benjamin, DK; Driscoll, T; Seibel, NL; Gonzalez, CE; Roden, MM; Kilaru, R; Clark, K; Dowell, JA; Schranz, J; Walsh, TJ. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrobial agents and chemotherapy. 2006;50:632-638.  Abstract
  • Benjamin, DK; Schelonka, R; White, R; Holley, HP; Bifano, E; Cummings, J; Adcock, K; Kaufman, D; Puppala, B; Riedel, P; Hall, B; White, J; Cotton, CM; S. aureus prevention investigators. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. Journal of Perinatology. 2006;26:290-295.  Abstract
  • Benjamin, DK; Smith, PB; Murphy, MD; Roberts, R; Mathis, L; Avant, D; Califf, RM; Li, JS. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA : the journal of the American Medical Association. 2006;296:1266-1273.  Abstract
  • Benjamin, DK; Stoll, BJ; Fanaroff, AA; McDonald, SA; Oh, W; Higgins, RD; Duara, S; Poole, K; Laptook, A; Goldberg, R; National Institute of Child Health and Human Development Neonatal Research Network. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006;117:84-92.  Abstract
  • Cotten, CM; McDonald, S; Stoll, B; Goldberg, RN; Poole, K; Benjamin, DK; National Institute for Child Health and Human Development Neonatal Research Network. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics. 2006;118:717-722.  Abstract
  • Garges, HP; Moody, MA; Cotten, CM; Smith, PB; Tiffany, KF; Lenfestey, R; Li, JS; Fowler, VG; Benjamin, DK. Neonatal meningitis: what is the correlation among cerebrospinal fluid cultures, blood cultures, and cerebrospinal fluid parameters?. Pediatrics. 2006;117:1094-1100.  Abstract
  • Tiffany, KF; Benjamin, DK; Palasanthiran, P; O'Donnell, K; Gutman, LT. Improved neurodevelopmental outcomes following long-term high-dose oral acyclovir therapy in infants with central nervous system and disseminated herpes simplex disease. Journal of Perinatology. 2005;25:156-161.  Abstract
  • Benjamin, DK; DeLong, E; Cotten, CM; Garges, HP; Steinbach, WJ; Clark, RH. Mortality following blood culture in premature infants: increased with Gram-negative bacteremia and candidemia, but not Gram-positive bacteremia. Journal of Perinatology. 2004;24:175-180.  Abstract
  • Benjamin, DK; DeLong, ER; Cotten, CM; Garges, HP; Clark, RH. Postconception age and other risk factors associated with mortality following Gram-negative rod bacteremia. Journal of Perinatology. 2004;24:169-174.  Abstract